HeartBeam Past Earnings Performance
Past criteria checks 0/6
HeartBeam's earnings have been declining at an average annual rate of -30.9%, while the Medical Equipment industry saw earnings growing at 15.3% annually.
Key information
-30.92%
Earnings growth rate
8.22%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | n/a |
| Return on equity | -3,185.98% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
BEAT: Slower Commercial Ramp Will Set Up Future Rebound After Recent Dilution
HeartBeam's updated analyst price target has shifted from $4.00 to $2.50 as analysts factor in expectations for a slower revenue ramp, modestly adjusted profit margins, and a higher future P/E, partly influenced by recent equity dilution and revised sales timelines following the Q1 update. Analyst Commentary Recent Street research on HeartBeam points to a more cautious tone, with several bearish analysts recalibrating their expectations after the Q1 update.
BEAT: Extended Funding Runway Will Support Longer Commercialization Ramp
HeartBeam's updated analyst price targets, which have shifted lower from prior levels such as $8 to $5 and $5.50 to $2.50, reflect analysts' expectations for a longer revenue ramp and the impact of recent equity dilution on fair value and profit margin assumptions. Analyst Commentary Recent Street research on HeartBeam presents a mixed picture, with analysts balancing expectations for a slower revenue ramp and share dilution against a constructive view on the company’s longer term execution potential.Concierge Cardiac Care And AI Collaboration Will Shape A Long Term Bullish View
Catalysts About HeartBeam HeartBeam develops portable, cable free 12 lead ECG technology for at home and ambulatory cardiac assessment. What are the underlying business or industry changes driving this perspective?
At Home ECG Clearances And AI Pipeline Will Transform Cardiac Care Over Time
Catalysts About HeartBeam HeartBeam develops portable, cable free ECG technology that lets patients capture clinical grade 12 lead readings at home or on demand. What are the underlying business or industry changes driving this perspective?Home Cardiac Diagnostics And AI Delays Will Restrain Progress Yet Eventually Support Potential Upside
Catalysts About HeartBeam HeartBeam develops a portable, cable free ECG system intended to give patients at home clinical grade 12 lead readings supported by remote cardiologist review. What are the underlying business or industry changes driving this perspective?Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...HeartBeam gets a new chief medical officer
HeartBeam (NASDAQ:BEAT) appoints renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He has also been a consultant to the US Food and Drug Administration for the past 20 years, focused on medical technology and data driven health analytics. Shares are up 2.37% premarket.HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%
HeartBeam (NASDAQ:BEAT) on Wednesday said it had been issued a patent from the U.S. Patent and Trademark Office which enables it to generate its credit card-sized AIMIGo 12-lead electrocardiogram (ECG) for the detection of heart attacks. Shares of the company rose 14.5% to $3.08 in early trading. “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” BEAT CEO Branislav Vajdic said in a statement. The newly issued patent - No. 11,445,963 B2 - expands on BEAT's granted and pending core patents for remote heart attack detection, the company said.HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks
HeartBeam (NASDAQ:BEAT) is trading 54% higher premarket after it received patent for a 12-lead electrocardiogram (ECG) patch monitor to detect acute coronary syndrome and cardiac arrhythmia by the United States Patent and Trademark Office. The company expects its ECG device to detect ACS diagnosis including myocardial infarction (heart attack) and angina. The newly issued patent expands on the HeartBeam’s previously granted US patent for a 12-lead ECG patch monitor technology. The patch patent follows HeartBeam’s already granted core patents for remote detection of heart attacks. Stock has been down ~66% YTD.HeartBeam GAAP EPS of $0.43 beats by $0.70
HeartBeam press release (NASDAQ:BEAT): Q2 GAAP EPS of $0.43 beats by $0.70. Shares -2.6%.Revenue & Expenses Breakdown
How HeartBeam makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -20 | 8 | 12 |
| 31 Dec 25 | 0 | -21 | 8 | 13 |
| 30 Sep 25 | 0 | -21 | 8 | 13 |
| 30 Jun 25 | 0 | -20 | 8 | 13 |
| 31 Mar 25 | 0 | -20 | 8 | 12 |
| 31 Dec 24 | 0 | -19 | 9 | 11 |
| 30 Sep 24 | 0 | -18 | 9 | 10 |
| 30 Jun 24 | 0 | -17 | 9 | 9 |
| 31 Mar 24 | 0 | -15 | 8 | 8 |
| 31 Dec 23 | 0 | -15 | 9 | 7 |
| 30 Sep 23 | 0 | -14 | 9 | 6 |
| 30 Jun 23 | 0 | -15 | 8 | 6 |
| 31 Mar 23 | 0 | -15 | 8 | 7 |
| 31 Dec 22 | 0 | -13 | 7 | 6 |
| 30 Sep 22 | 0 | -11 | 7 | 4 |
| 30 Jun 22 | 0 | -9 | 5 | 3 |
| 31 Mar 22 | 0 | -6 | 3 | 1 |
| 31 Dec 21 | 0 | -4 | 2 | 0 |
| 30 Sep 21 | 0 | -3 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
Quality Earnings: BEAT is currently unprofitable.
Growing Profit Margin: BEAT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BEAT is unprofitable, and losses have increased over the past 5 years at a rate of 30.9% per year.
Accelerating Growth: Unable to compare BEAT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BEAT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).
Return on Equity
High ROE: BEAT has a negative Return on Equity (-3185.98%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 03:53 |
| End of Day Share Price | 2026/07/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HeartBeam, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| William Sutherland | Benchmark Company |
| Anderson Schock | B. Riley Securities, Inc. |